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Abstract
Purpose: Genomic profiling of tumor biopsies from advanced gastrointestinal and anal cancers is
increasingly used to inform treatment. In some cases, tissue biopsy can be prohibitive, and we
sought to investigate whether analysis of blood-derived circulating tumor DNA (ctDNA) may
provide a minimally invasive alternative.
Experimental Design: Hybrid capture-based genomic profiling of 62 genes was performed on
blood-based ctDNA from 417 patients with gastrointestinal carcinomas to assess the presence of
genomic alterations (GA) and compare with matched tissue samples.
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Results: Evidence of ctDNA was detected in 344of417 samples (82%), and of these, ≥1
reportable GA was detected in 89% (306/344) of samples. Frequently altered genes were TP53
(72%), KRAS (35%), PIK3CA (14%), BRAF (8%), and EGFR (7%). In temporally matched
ctDNA and tissue samples available from 25 patients, 86% of alterations detected in tissue were
also detected in ctDNA, including 95% of short variants, but only 50% of amplifications.
Conversely, 63% of alterations detected in ctDNA were also detected in matched tissue. Examples
demonstrating clinical utility are presented.
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Conclusions: Genomic profiling of ctDNA detected potentially clinically relevant GAs in a
significant subset of patients with gastrointestinal carcinomas. In these tumor types, most
alterations detected in matched tissue were also detected in ctDNA, and with the exception of
amplifications, ctDNA sequencing routinely detected additional alterations not found in matched
tissue, consistent with tumor heterogeneity. These results suggest feasibility and utility of ctDNA
testing in advanced gastrointestinal cancers as a complementary approach to tissue testing, and
further investigation is warranted.

Introduction

Author Manuscript

The treatment of gastrointestinal cancers is influenced by the presence or absence of
prognostic and predictive genomic alterations (GA), following precedents set in non-small
cell lung cancer and other solid tumors. Extended RAS and BRAF testing is widely
performed in colorectal carcinoma to guide the use of anti-EGFR antibody therapies, which
have shown particular efficacy in patients with tumors wild type for KRAS, NRAS, and
BRAF mutations (1, 2). Similarly, MET and HER2 (ERBB2) amplification have each
emerged as negative predictors of response to EGFR antibodies, and simultaneously as
putative molecular targets themselves in tumor types, including gastric cancer and colorectal
carcinoma (3–6). Testing gastroesophageal adenocarcinomas for HER2 overexpression by
IHC and/or gene amplification by FISH is currently considered a standard of care for
advanced disease (7). Additional molecular targets both predicting lack of benefit from
EGFR antibodies and predicting sensitivity to matched targeted therapies continue to be
elucidated in tumors of the gastrointestinal tract and anus (8, 9), necessitating methods for
comprehensive assessment.
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Currently, tissue-based genomic testing of cancer specimens remains the gold standard, but
assays utilizing sequencing of circulating tumor DNA (ctDNA) isolated from blood samples
have recently been introduced into clinical care. Clonal evolution and tumor heterogeneity
are known to impact the response and resistance to targeted therapies in gastrointestinal
cancers, but serial or simultaneous tissue sampling of multiple metastatic lesions is
problematic (10, 11). Blood-based genomic profiling assays provide a noninvasive
alternative to traditional tissue biopsies and may provide complementary genomic
information to tissue-based testing. As more patients receive targeted therapies, sequencing
pretreatment and postprogression samples will become increasingly important. In the current
study, we analyze results from ctDNA-based genomic profiling using a 62-gene assay from
over 400 patients with carcinomas of the gastrointestinal tract and anus. Comparison with
temporally matched tissue samples and large tissue databases, as well as examples of clinical
utility, is described.

Author Manuscript

Materials and Methods
Blood samples were obtained for 417 patients with primarily late-stage carcinomas of the
gastrointestinal tract or anus with consecutive genomic profiling results reported. Genomic
profiling of ctDNA was performed on samples submitted by clinicians as part of routine
clinical care between May 2016 and June 2017. Testing was performed in a CLIA-certified/
CAP-accredited laboratory (Foundation Medicine Inc.). Approval for this study, including a
waiver of informed consent and a HIPAA waiver of authorization, was obtained from the
Western Institutional Review Board (Protocol No. 20152817).

Author Manuscript
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Twenty milliliters of peripheral whole blood was collected in Cell-Free DNA BCT tubes
(Roche/Ariosal or Strek) for genomic profiling of ctDNA. Plasma was isolated, and ≥20 ng
ctDNA was extracted to create adapted sequencing libraries before hybrid capture and
sample-multiplexed sequencing (Illumina HiSeq 2500 or 4000) to a median unique coverage
depth of 7,587× for 62 genes (Supplementary Table S1; ref. 12). Results were analyzed for
alterations at low allele frequencies (AF), including substitutions (AF ≥ 0.1%), short
insertions/deletions (indels AF ≥ 0.1%), rearrangements, and copy number amplification. AF
represents the percentage of mutant DNA allele reads relative to total DNA allele reads
(mutant plus wild type). Custom filtering was applied to report GAs and remove benign
germline events as described previously (13). Maximum somatic allele frequency (MSAF)
measures the AF of all somatic alterations (including reportable GAs, variants of unknown
significance, and synonymous mutations) identified per sample; alterations in the ExAC
database are removed from the alteration list for MSAF calculation as they are likely
germline, and dbSNP variants are also excluded. The maximum AF identified out of all
alterations measured is defined as the MSAF, which can provide an estimate of the ctDNA
fraction in blood. Clinically relevant GAs were defined as alterations that are targetable by
anticancer drugs currently available on the market or in registered clinical trials.
Twenty-five patients in this series had a paired tissue sample that was sequenced using
hybrid capture-based genomic profiling (FoundationOne) according to previously published
methods (13, 14). For comparative analyses with prior studies, data from the
FoundationCORE database (tissue samples analyzed using the FoundationOne assay),
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TCGA (15), and the Giannakis and colleagues’ study (16) were extracted from cBioPortal
(17) in July 2017. Ordinal relationships were examined using the Mann-Whitney U test;
categorical relationships were examined using Pearson χ2 test with Yates’ continuity
correction when applicable.

Results
Patient characteristics

Author Manuscript

Hybrid capture-based genomic profiling was performed on ctDNA isolated from blood
samples collected from 417 patients with primarily late-stage carcinomas of the
gastrointestinal tract or anus. The disease histologies included colorectal adenocarcinoma
(72%), gastroesophageal junction adenocarcinoma (GEJ, 11%), gastric adenocarcinoma
(8.9%), anal squamous cell carcinoma (3.1%), esophageal carcinoma (2.4%), small-bowel
adenocarcinoma (1.6%), or high-grade gastrointestinal neuroendocrine carcinoma (0.5%).
The median patient age was 60 years (range, 27–93), and 43% of patients were women
(Table 1).
GAs identified in the ctDNA of patients with gastrointestinal cancers
Evidence of ctDNA in the blood, as approximated using a MSAF >0, was detected in 82%
(344/417) of cases. The median MSAF across all cases was 2.36% (range, 0%−89.9%), and
among cases with evidence of ctDNA present, at least one reportable GA was detected in
89% (306/344) of cases, for an average of 2.28 GA per case. However, both the fraction of
cases with detectable ctDNA and consequently the median MSAF varied across disease
histologies, with the highest average number of GA detected in colorectal carcinoma (Fig. 1;
Table 1).

Author Manuscript
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Among 344 cases with evidence of ctDNA in the blood, the most frequently altered genes
were TP53 (72%), KRAS (35%), PIK3CA (14%), BRAF (8%), and EGFR (7%; Fig. 2A).
Potentially actionable GAs informing selection of matched targeted therapies and clinical
trials or predicting lack of response to EGFR antibody therapies were identified (Fig. 2B and
C). RAS/RAF/MEK pathway alterations (48%), PI3K pathway alterations (17%), point
mutation, amplification or fusion of receptor tyrosine kinases (RTK, 18%), and BRCA1/2
alterations (5%) were present across histologies, with a total of 66% (228/344) of cases
harboring at least one alteration in one or more of these pathways. HER2 (ERBB2)
alterations were observed in 5% (17/344) of cases and included copy number amplification
in 2.3%, activating point mutation in 2.0%, or both in 0.6%. EGFR extracellular domain
(ECD) mutations within the cetuximab and panitumumab-binding domains, including
V411D/G, S464L, S465E/R, and S492R, were found in 3.2% (11/344) of cases, all of which
were colorectal carcinomas. Three cases harbored multiple EGFR ECD mutations and the
cis/trans relationship could be evaluated for 2 cases, both of which showed that all the
mutations were in trans (Supplementary Fig. S1). Eight potentially targetable RTK fusions
were detected in 7 cases and included GOPC-ROS1 (2 cases), SLC24A2-ROS1, STRNALK, CCDC6-RET, KIF5B-PDGFRA, EGFR-SEPT14, and FGFR3-TACC3.
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Comparison of GAs identified in ctDNA with paired tissue samples and prior genomic
studies of tissue
Frequencies of short variant alterations in commonly mutated genes observed in the 344
ctDNA samples included in this study were largely similar to those observed among 15,948
tissue samples included in the FoundationCORE database for patients with matched disease
histologies (Fig. 3A). These included TP53 (72.1% vs. 73.6%), KRAS (34.0% vs. 41.5%),
PIK3CA (14.0% vs. 15.5%), and BRAF (8.1% vs. 6.7%). However, gene amplification was
less frequently detected in ctDNA samples from this study compared with samples from
similar patients in the FoundationCORE database (Fig. 3B). FLT3, HER2, and MYC were
amplified in 3.5%, 2.9%, and 2.3% of ctDNA samples, respectively, and in 5.5%, 5.2%, and
8.6% of tissue samples in the FoundationCORE database, respectively (P = 0.13, P = 0.07,
and P <0.001).
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For 25 patients included in this study, DNA from matched tissue and blood samples
collected within 30 days was available, and samples were analyzed using similar hybrid
capture-based genomic profiling assays. Matched samples without evidence of ctDNA in the
blood were excluded from analysis. In total, 57 alterations across the 25 cases were detected
in tissue samples, of which 49 of these alterations (86%) were also detected in temporally
matched ctDNA. This included 95% (42/44) of short variant alterations, 50% (6/12) of
amplifications, and 1/1 rearrangements (Fig. 4; Supplementary Table S2). Conversely, 63%
(49/78) alterations detected in ctDNA samples were also detected in DNA isolated from
temporally matched tissue samples. Notably, 4/4 EGFR ECD mutations and 4/5 kinase
rearrangements were found in ctDNA but not in paired tissue samples (Fig. 4A). Only
alterations covered by both assays were assessed. No significant difference in concordance
was observed when primary versus metastatic tissue biopsies was compared with temporally
matched ctDNA. For 18 metastatic tissue biopsies and 7 primary tissue biopsies, 85%
(33/39) and 89% (16/18) of alterations detected in tissue, respectively, were also found in
matched ctDNA samples. Of alterations detected in ctDNA, 61% (33/54) and 67% (16/24),
respectively, were also detected in matched metastatic or primary tissue biopsies. Similarly,
among tissue samples from the liver (n=10), 20 of 24 (83%) alterations found in tissue were
also found in ctDNA, and 20 of 31 (65%) alterations found in ctDNA were also found in
tissue.
Case studies supporting clinical utility of ctDNA testing in patients with gastrointestinal
and anal cancers

Author Manuscript

Clinical outcomes were sought for cases with potentially actionable alterations detected in
ctDNA. Follow-up was availabe from the treating physician for 13 patients (Table 2). Of
these, 2 (ROS1 fusion, FGFR2 amplification) are responding to current systemic therapy and
will pursue trial enrollment at progression, 5 received matched targeted therapies, approved
in other tumor types or through clinical trials, based on results from ctDNA profiling, and 2
had ctDNA testing done after targeted therapy, and a potential mechanism of acquired
resistance was discovered. One patient was lost to follow-up, and 3 passed away without
receiving targeted therapy.
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The 5 patients of whom we are aware received matched targeted therapy each had stage IV
disease at the time CGP was performed. In the first case (Table 2, case 3), a STRN-ALK
fusion was detected by both genomic profiling of tissue and ctDNA, despite the same tumor
tissue being initially negative for ALK by local IHC testing. Details of this case have been
published (18); however, since the original report, the patient relapsed on standard therapy
and has enrolled on a clinical trial of a kinase inhibitor targeting ALK. In the second case
(Table 2, case 4), an FGFR2 C382R activating mutation was detected and the patient
subsequently initiated treatment with pazopanib, a multikinase inhibitor with anti-FGFR2
activity. In the third case (Table 2, case 5), ctDNA testing detected multiple activating HER2
mutations, and based on this result, the patient is now enrolled on a clinical trial and
receiving matched targeted therapy with trastuzumab plus pertuzumab. In the fourth case
(Table 2, case 6), ctDNA testing revealed a GOPC-ROS1 fusion. The patient began
treatment with the ALK/ROS1 inhibitor crizotinib and had clinical improvement and
shrinkage of multiple lesions within 3 months of initiating therapy (Supplementary Fig. S2).
Breaks in treatment due to infection requiring hospitalization and later due to compliance
issues correlated with increased CEA levels and progressive disease; however, resumption of
crizotinib resulted in symptom improvement. Because of persistent progressive disease, the
patient was then switched to ceritinib, a second-generation ALK/ROS1 inhibitor, with a
clinical response, but discontinued due to gastrointestinal toxicity and later expired. In the
fifth case (Table 2, case 7), ctDNA testing detected an HER2-activating mutation and
coamplification. Notably, the patient was originally diagnosed 15 months prior to ctDNA
testing, and HER2 IHC performed on a previous biopsy had been negative, and therefore,
the patient did not receive HER2-targeted therapy at that time. When ctDNA testing was
performed, the patient was declining rapidly but derived symptomatic improvement and
clinical benefit on palliative trastuzumab monotherapy.
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Two patients underwent treatment with targeted therapy following tissue-based genomic
profiling (FoundationOne), and later had ctDNA testing performed at progression. The first
patient (Table 2, case 8) was treated on a clinical trial of trastuzumab + pertuzumab.
Following a 2-year response, a blood sample was collected upon progression due to
difficulty in obtaining a biopsy in the setting of bone-only disease. Genomic profiling of
ctDNA revealed the initial HER2 amplification as well as a PIK3CA mutation not present in
the prior tissue sample. PIK3CA mutation is a known resistance mechanism to HER2targeted therapy, particularly in breast cancer (19, 20). Of note, no outlier lesions concerning
for second primary lesions, such as a breast primary, were identified in this patient, and the
bone disease was determined to be metastatic colorectal adenocarcinoma. The second
patient (Table 2, case 9) was treated with first-line trastuzumab, followed by paclitaxel and
ramucirumab. At progression on first-line therapy, ctDNA testing revealed the initial HER2
amplification as well as a focal MET amplification not present in the prior tissue sample.

Discussion
Herein, we report results from genomic profiling of ctDNA from 417 patients with
carcinomas of the gastrointestinal tract or anus. Evidence of ctDNA in the blood, as
estimated by MSAF > 0, was detected in 82% of cases, similar to recent studies in colon
cancer (21, 22). Among cases with evidence of ctDNA, at least one reportable GA was
Clin Cancer Res. Author manuscript; available in PMC 2018 August 05.
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detected in 89% of cases with an average of 2.28 reportable alterations per case. Potentially
actionable alterations in the RAS/RAF/MEK pathway (48%) and PI3K pathway (17%) were
common, and inactivating DNA repair pathway mutations in BRCA1/2 (5%) were observed
across anatomic tumor types. Activating alterations in RTKs, including EGFR, HER2, MET,
FGFR1/2/3, ALK, ROS1, RET, and PDGFRA, were observed in 18% of cases, including
HER2 amplification or point mutation in 5% of cases. RTK fusions, rare potentially
targetable driver events in gastrointestinal cancers (18, 23, 24), were detected in 2% of cases,
which is notably higher than in previously published frequencies in gastrointestinal tissue
samples (9, 25). Examples of clinical utility were observed in a significant fraction of
patients in whom potentially actionable alterations were detected in ctDNA and follow-up
was available (Table 2). However, it should be noted that the role of ctDNA testing in
gastrointestinal cancers remains largely investigational, and alterations identified herein are
largely utilized to identify matched off-label therapies or genomically matched clinical trials.
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The frequency of gene amplification detection was notably lower in ctDNA samples
compared with that detected in tissue samples from both the FoundationCORE tissue
database (representing similar disease ontologies), as well as to published tissue studies in
colorectal carcinoma (15, 16). In contrast, the spectrum and incidence of genes with short
variant alterations was similar to that observed in tissue samples from patients with
gastrointestinal cancers, supporting the ability of ctDNA profiling to reflect tissue-based
characterization. In recent studies comparing ctDNA and tissue samples in colorectal
carcinoma patients, similar rates of short variant alterations to those seen here were also
observed for frequently altered genes (21, 22). However, in one study (21), reported
frequencies of EGFR and MET amplification in ctDNA samples were notably enriched
compared with ctDNA results observed here and relative to published tissue studies of
colorectal carcinoma (21). In another study (22), although short variant alteration
frequencies were reported, the prevalence of gene amplifications and fusions detected in
cell-free DNA samples were not included for the majority of cases (22).
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Although concordance for short variant alterations detected in tissue samples with those
detected in temporally matched ctDNA was quite high (95%), only 50% (6/12) of gene
amplifications detected in tissue were detected in matched ctDNA samples. This is similar to
what has been observed in other ctDNA studies in solid tumors (26, 27). In gastrointestinal
cancers, detection of amplification of potentially targetable RTKs, including HER2 and
MET, is likely to be clinically relevant, as these events have been shown to mediate acquired
resistance and are themselves targetable using therapies currently approved in other tumor
types or in active clinical trials, including the NCI-MATCH and TAPUR studies (3, 6, 28).
In fact, in a recent study of 22 pan-RAS/BRAF/HER2/MET wild-type colorectal carcinoma
cases progressing on EGFR antibody therapeutic regimens, tissue and ctDNA analyses at
cetuximab or panitumumab progression supported KRAS mutations and HER2 or MET
amplification as the dominant mediators of clinical resistance (27). Furthermore, EGFR
amplification is an emerging target in gastric and esophageal cancers (29–31). However, in
the relatively small analysis of paired samples in this study, no HER2 or MET amplifications
(and just one EGFR amplification, found in tissue only) were observed in either subset, so
concordance analysis was limited for these specific gene amplifications. Eight GAs across 6
patient cases were identified in tissue and not in paired ctDNA, including 6 gene
Clin Cancer Res. Author manuscript; available in PMC 2018 August 05.
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amplifications (PIK3CA, CDK6, FLT3, KRAS, EGFR, and MYC) and two short variant
mutations (Supplementary Table S2). However, in the majority of these cases, the
amplifications not detected in ctDNA were identified in the setting of one or more other
known and potentially targetable driver alterations, so the clinical significance of these gene
amplifications is unclear. For the two cases with short variant mutations not detected in
ctDNA, one case harbored an NF1 truncating alteration was identified only in matched
tissue, which is potentially actionable through clinical trial enrollment or treatment with offlabel therapies; in the second case, an activating NRAS G60E mutation was detected in
paired tissue only. However, the actionability of this alteration in GEJ adenocarcinoma is not
established. Notably, 7 of 7 KRAS mutations detected in tissue were also detected in
matched ctDNA.
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When we compared the ctDNA fraction, as estimated by MSAF, in samples where at least
one amplification event was detected versus those with no amplification, we found that cases
with amplification present had significantly higher MSAF than those without
(Supplementary Fig. S3A). This may suggest that, similar to what has recently been reported
in a ctDNA breast cancer study (32), higher levels of ctDNA in a blood sample may be
necessary to reliably detect gene amplifications. Interestingly, the predicted copy number for
amplified genes in paired tissue samples was not significantly different for amplifications
found in both tissue and blood compared with amplifications found only in the paired tissue
sample. We acknowledge that this observation is preliminary as the number of samples and
amplification events available for analysis was relatively small (Supplementary Fig. S3B).
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EGFR mutations were notably more common in ctDNA (5.8%) samples compared with
tissue samples in the FoundationCORE database (0.8%) for gastrointestinal carcinomas, and
the majority of EGFR mutations detected were in the cetuximab/panitumumab-binding
region of the ECD, which have been shown to mediate resistance to these anti-EGFR
therapies (10) that are approved and commonly used for the treatment of KRAS wild-type
colorectal carcinoma. This observed enrichment in ctDNA versus tissue biopsies likely
reflects the subclonal nature of these mutations, although other factors may also contribute
to the discrepancy. Of note, EGFR mutations were more common in the other two published
tissue studies examined relative to FoundationCORE; however, this may be expected as
these datasets included only colorectal carcinoma cases and excluded other gastrointestinaltype malignancies less likely to have received anti-EGFR therapies. Similar observations
regarding subclonal EGFR ECD mutations were noted in a recent large study of blood-based
cell-free DNA samples in colorectal carcinoma, including recurrent mutations at EGFR
V441D/G, which had not been previously reported (22). This study also noted treatment
history with EGFR antibodies in all patients with samples harboring these mutations for
whom clinical data were available, further suggesting a role for ECD mutations in
cetuximab/panitumumab resistance.
Although 95% (42/44) short variant alterations detected in tissue were also detected in
temporally matched ctDNA samples (restricting to genes represented in both panels), only
63% (49/78) short variant alterations detected in ctDNA were also detected in matched
tissue. Furthermore, only 1 of 5 kinase rearrangements detected in ctDNA were detected in
matched tissue. Therefore, blood-based ctDNA testing may provide added value beyond
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tissue testing to detect multiple primary drivers or diverse mechanisms of acquired resistance
in a single patient. However, large collaborative efforts with clinically annotated tissue and
ctDNA are critical to determine the relative importance of multiple potential drivers, and to
establish how these genomic data may be useful in making clinical treatment decisions.
Tissue biopsy done in parallel with ctDNA may be useful to determine which heterogenous
alterations are present in a given tumor, or to determine the genomic profile of a given lesion
of particular clinical concern (11). The optimal method to comprehensively assess tumoral
evolution and acquired resistance is not known, but our data suggest there is likely additional
value in utilizing ctDNA for repeat genomic profiling to capture dynamic changes in a
patient’s tumor genomic profile over time, particularly during the course of treatment with
targeted therapy (28, 33).
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Other studies of ctDNA profiling in gastrointestinal cancers have focused on colon cancer,
and most have been limited in size, and in some cases restricted to hotspot alterations in a
limited set of genes (21, 28, 34). Strickler and colleagues recently reported cell-free DNA
genomic profiling results for over 1,000 colorectal carcinoma patients, but analysis was
largely focused on short variant alterations, and no comparison with paired tissue samples
was available (22). Alternative applications for ctDNA, including detection of residual
disease and early recurrence, rather than identification of actionable GAs, have been the
focus of other studies and are not formally examined in our analysis (35, 36). Despite the
promise of ctDNA, there are clear disadvantages in relying solely on ctDNA testing,
including lack of sufficient ctDNA in approximately 18% of samples, low purity (MSAF) of
ctDNA, which can lead to diminished ability to reliably detect gene amplifications, and
overall smaller gene panels with ctDNA versus tissue, which limit the total number of
assessable alterations. A recent study in colorectal carcinoma noted that in over 25% of
patients studied, a potentially actionable alteration was identified in tissue that was not
detected in ctDNA (21). Comprehensive tissue-based genomic profiling assays have the
capability to report additional GAs and signatures in gastrointestinal cancers, specifically
microsatellite instability, tumor mutational burden, and PD-L1 IHC, all of which have
implications for the role of immunotherapies in gastrointestinal cancers. We anticipate
improving technological methods will allow more comprehensive assessment from ctDNA
in the future, but currently available ctDNA assays remain limited.
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The limited accessibility of tumor tissue in advanced cancer patients represents a significant
clinical challenge. Blood-derived ctDNA may provide an alternative approach for genomic
profiling in cases where tissue biopsy is prohibitive, and ctDNA testing may have the
additional advantage of identifying heterogenous alterations not present in a single tumor
site; however, the clinical implications of detection of such alterations requires further
investigation. ctDNA testing is currently limited relative to tissue testing in the detection of
gene amplification, and currently available ctDNA assays are typically less comprehensive
than available tissue-based assays. Thus, we conclude that ctDNA testing should be utilized
as a complementary methodology to tissue-based genomic profiling and may be particularly
useful in the setting of acquired resistance, or in patients when tissue biopsy is challenging.
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Translational Relevance
Genomic testing to gain predictive and prognostic information has increasingly become
part of clinical care for patients with advanced gastrointestinal cancers. Tissue testing
remains the gold standard; however, blood-derived circulating tumor DNA (ctDNA) has
emerged as a minimally invasive alternative. In this series, we present results from a large
cohort of patients with advanced gastrointestinal malignancies whose samples were
tested prospectively during routine clinical care using hybrid capture-based ctDNA
profiling. For a subset of cases, temporally matched tissue samples assayed using a
similar platform were analyzed for concordance and comparison. This study highlights
the utility of noninvasive ctDNA testing in gastrointestinal cancers, particularly in the
setting of acquired resistance to targeted therapies. The limitations of ctDNA versus
tissue-based genomic profiling are discussed.
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Figure 1.

ctDNA fraction estimated across gastrointestinal disease histologies. MSAF was used to
estimate the ctDNA fraction in a given sample. MSAF was significantly greater for all
gastrointestinal ctDNA cases versus gastric carcinoma ctDNA cases (*, P = 0.011) and in
colorectal carcinoma ctDNA cases versus gastric ctDNA cases (**, P = 0.003). Box-andwhisker plots: box spans first and third quartiles, the median is denoted by the horizontal
line in the box, and whiskers indicate maximum and minimum values within 1.5× the
interquartile range.
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Author Manuscript

GAs identified in ctDNA from patients with gastrointestinal or anal carcinomas. Includes
samples with evidence of ctDNA in the blood (MSAF >0). All gastrointestinal samples (n =
344), colorectal carcinoma (n = 258), GEJ (n = 36), gastric adenocarcinoma (n = 25). A,
Longtail of frequently altered genes in carcinomas of the gastrointestinal tract or anus. B,
Frequency of major pathway alterations across gastrointestinal disease histologies. RTK
alterations include mutation, amplification, or fusion of EGFR; amplification or mutation of
MET, ERBB2, FGFR1, and FGFR2; and fusion only of ALK, ROS1, RET, PDGFRA, and
FGFR3. RAS/RAF/MEK pathway alterations include mutation or amplification of KRAS,
NRAS, BRAF, RAF1, or MEK1. PI3K pathway alterations include amplification or
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mutation of PIK3CA, and mutation of AKT1 or PTEN. C, Distribution of individual gene
alterations within pathways defined in B.
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Figure 3.

GAs in ctDNA from patients with carcinomas of the gastrointestinal tract or anus compared
with tissue. Comparison of the most frequently mutated (A) or amplified (B) genes observed
in ctDNA in this study with tissue-based genomic profiling of carcinomas of the
gastrointestinal tract of anus (FoundationCORE database) or with published tissue-based
genomic profiling studies of primarily early-stage colorectal carcinoma (TCGA 2012 and
Giannakis and colleagues 2016). Copy number data were not available in the Giannakis and
colleagues study. Data from the TCGA and Giannakis studies were extracted from
cBioPortal. *, TERT alterations were not assessed in the Giannakis (gray bars) or TCGA
(blue bars) series.
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Figure 4.
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Concordance between GAs found in ctDNA and matched tissue from 25 patients with
gastrointestinal carcinomas. A, Days between ctDNA and tissue collection, MSAF, and
disease histology are shown. CR, colorectal adenocarcinoma; G, gastric adenocarcinoma;
RE, rearrangement. Concordant/shared GAs are in blue, GAs found only in tissue are in red,
and GAs found only in ctDNA are in pink. For samples with multiple unique mutations in a
given gene, the number of mutations is indicated. B, Venn diagrams of concordant and
discordant alterations by class. Blue, GAs found in both ctDNA and tissue; pink, GAs found
only in ctDNA; red, GAs found only in tissue.
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Characteristics of gastrointestinal ctDNA samples by anatomic tumor location
All cases

CRC

GEJ

Gastric

Anus SCC

Esophagus

SBA

Neuroendocrine

Cases, n

417

302

46

37

13

10

7

2

Median patient age
(range), years

60 (27–93)

59 (27–92)

64 (31–93)

60 (33–89)

61 (50–83)

66 (53–82)

61 (50–90)

48 (40–56)

Gender

43F: 57M

57F: 43M

24F: 76M

38F: 62M

62F: 38M

30F: 70M

57F: 43M

50F: 50M

MSAF >0 (%)

344 (82)

256 (85)

36 (78)

25 (68)

9 (69)

10 (100)

5 (71)

1 (50)

Median MSAF

2.36%

3.19%

1.38%

0.35%

0.54%

2.54%

0.42%

43.0%

2.28

2.37

1.94

1.76

2.44

2.3

2.2

0.5

Avg. GA/case

a

Abbreviations: CRC, colorectal carcinoma; SBA, small-bowel adenocarcinoma.

a

Includes only cases with MSAF >0.
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Characteristics of patients with clinical follow-up available
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Patient

Disease histology

Age

Gender

Stage

Potentially targetable
GAs identified in ctDNA

1

Rectum adenocarcinoma

41

M

IV

SLC34A2-ROS1 fusion

Currently receiving first-line SOC
therapy, will
consider trial of ROS1 inhibitor at
progression

2

Gastric adenocarcinoma

64

M

IV

FGFR2 amplification

Currently responding to immune
checkpoint
inhibitor therapy, will consider trial of
FGFR2
inhibitor at progression

3

Colon adenocarcinoma

62

F

IV

STRN-ALK fusion

Enrolled in clinical trial of ALK inhibitor

4

Anus SCC

75

F

IV

FGFR2 C382R

Began treatment with pazopanib based
on FGFR
activity

5

Colon adenocarcinoma

59

M

IV

HER2 D769Y, R678Q,
S310Y

Enrolled in clinical trial of matched
targeted
therapy with trastuzumab + pertuzumab

6

Small-bowel adenocarcinoma

54

F

IV

GOPC-ROS1 fusion

Clinical response to crizotinib, then
ceritinib upon
progression of disease

7

Esophagus adenocarcinoma

53

M

IV

HER2 amplification,
HER2 D769Y

Symptomatic improvement during 7week
treatment with trastuzumab, passed away
due
to advanced disease before scans were
performed

8

Rectum adenocarcinoma

37

F

IV

HER2 amplification,
PIK3CA N345K

ctDNA testing postprogression on
trastuzumab
+ pertuzumab trial detected PI3K
mutation

Treatment information

a

Author Manuscript

not present in tissue tested pretreatment.
Treated on a trastuzumab emtansine
(TDM1)based protocol and passed away 8
months
after ctDNA testing.
9

GEJ adenocarcinoma

78

M

IV

HER2 amplification, MET
amplification

ctDNA testing postprogression on
trastuzumabcontaining therapydetected MET
amplification

a

not present in tissue tested pretreatment.
Developed a malignant biliary
obstruction; had
a rapid clinical decline and was unable to
receive a MET-directed or dual-targeted
therapy.

Author Manuscript

10

Rectum adenocarcinoma

70

M

IV

HER2 S310Y

Lost to follow-up

11

Duodenum adenocarcinoma

77

F

IV

HER2 D769N, S310F,
V777M

Passed away before receiving targeted
therapy

12

Esophagus carcinoma

75

M

IV

METamplification

Passed away before receiving targeted
therapy

13

Gastric adenocarcinoma

43

F

IV

METamplification

Passed away before receiving targeted
therapy

NOTE: Age and stage indicate time when ctDNA testing was performed.
Abbreviation: SOC, standard of care.
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Pretreatment testing of DNA isolated from a tissue biopsy was performed using the parallel FoundationOne platform.

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript
Clin Cancer Res. Author manuscript; available in PMC 2018 August 05.

